Study details
Enrolling now
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT IDNCT07071155ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Ages
18–100
Locations
1 site in MD
What this study is about
This EARLY_Phase 1 study is testing Azacitidine in people with chronic myelomonocytic leukemia.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVsubcutaneous
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
azacitidine, momelotinib
Drug routes
injection, subcutaneous, oral (Oral Tablet)
Endpoints
Secondary: Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), Number of participants who experience a grade 3 or higher adverse events or severe event, Patient Global Impression of Change (PGIC)
Body systems
Oncology